



## Erratum

### Erratum to “Guidelines for the medical treatment of idiopathic pulmonary fibrosis” <[Arch. Bronconeumol. 53 (2017) 263–269]>☆



### Fe de errores de «Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática» <[Arch Bronconeumol. 53 (2017) 263–9]>

Antoni Xaubet,<sup>a,b,\*</sup> María Molina-Molina,<sup>b,c</sup> Orlando Acosta,<sup>d</sup> Elena Bollo,<sup>e</sup> Diego Castillo,<sup>f</sup> Estrella Fernández-Fabrellas,<sup>g</sup> José Antonio Rodríguez-Portal,<sup>b,h</sup> Claudia Valenzuela,<sup>i</sup> Julio Ancochea<sup>i</sup>

<sup>a</sup> Servicio de Neumología, Hospital Clínic, Barcelona, Spain

<sup>b</sup> Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain

<sup>c</sup> Unidad Funcional del Intersticio Pulmonar (UFIP), Servicio de Neumología, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

<sup>d</sup> Servicio de Neumología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

<sup>e</sup> Servicio de Neumología, Complejo Asistencial Universitario de León, León, Spain

<sup>f</sup> Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

<sup>g</sup> Servicio de Neumología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

<sup>h</sup> Servicio de Neumología, Hospital Universitario Virgen del Rocío, Sevilla, Spain

<sup>i</sup> Servicio de Neumología, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain

Several errors have been detected in **Tables 1 and 5**, in **Fig. 1**, and in the text of the article “Guidelines for the medical treatment of idiopathic pulmonary fibrosis” [Arch Bronconeumol. 2017;53:263–9]”.

The following tables are the correct versions:

**Table 1**

CAPACITY-1 and -2 and ASCEND Clinical Trials: Methodology and Clinical Features of IPF Patients Included.

	CAPACITY-1 and -2 (n=779)	ASCEND (n=555)
Age (years)	40–80	40–80
FVC (inclusion criterion)	≥50%–90%	50–90%
DLCO (inclusion criterion)	≥35%–90%	≥30%–90%
Phase	III	III
Study duration (weeks)	72	52
UIP on HRCT	92%	95.7%
Initial FVC (mean)	74.1%	67.8%
Initial DLCO (mean)	47%	43.7%

DLCO: carbon monoxide diffusing capacity; FVC: forced vital capacity; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia.

**Table 5**

TOMORROW and INPULSIS Clinical Trials: Methodology and Clinical Features of IPF Patients Included.

	TOMORROW (n=422, 85 at doses of 150 mg/12 h)	INPULSIS-1 and -2 (n=1066)
Age (years)	>40	>40
FVC (inclusion criterion)	≥50%	≥50%
DLCO (inclusion criterion)	30%–79%	30%–79%
Phase	II	III
Study duration (weeks)	52	52
UIP on HRCT	38.8%	76%
Initial FVC (mean)	78.1%	79.5%
Initial DLCO (mean)	–	47%

DLCO: carbon monoxide diffusing capacity; FVC: forced vital capacity; HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia.


The following Fig. 1 is the correct version:

DOI of original article: <http://dx.doi.org/10.1016/j.arbr.2017.03.001>

☆ Please cite this article as: Xaubet A, Molina-Molina M, Acosta O, Bollo E, Castillo D, Fernández-Fabrellas E, et al. Fe de errores de «Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática» [Arch Bronconeumol. 53 (2017) 263–9]. Arch Bronconeumol. 2017;53:657–658.

\* Corresponding author.

E-mail address: [axaubetmir@gmail.com](mailto:axaubetmir@gmail.com) (A. Xaubet).



**Fig. 1.** IPF pharmacological treatment algorithm. FVC: forced vital capacity; DL<sub>CO</sub>: carbon monoxide diffusing capacity.

The following text is the correct version:

- Page 3, section “Nintedanib (Ofev®)”, line 47. Where it says: “In the INPULSIS studies, patients with cardiovascular risk were excluded, so safety in this population could not be determined (Table 3). Table 4 shows nintedanib drug interactions.”, it should say: “Table 4 shows nintedanib drug interactions.”
- Page 5, section “Antifibrotics in Clinical Trials”, line 23. Where it says “Other combinations of pirfenidone or nintedanib with other new antifibrotics, initiated before either drug received marketing approval, are also ongoing ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)), including pirfenidone±lebrikizumab (RIFF study), pirfenidone or nintedanib±PRM-151 (PROMEDIOR study), pirfenidone±vismodegib (GB29764 study), pirfenidone±sildenafil, nintedanib+/-sildenafil (INSTAGE study) and other clinical trials in progress such as NCT02606877 (nintedanib+pirfenidone and the INMARK study.”

([www.clinicaltrials.gov](http://www.clinicaltrials.gov)), including pirfenidone±lebrikizumab (RIFF study), pirfenidone or nintedanib±PRM-151 (PROMEDIOR study), pirfenidone±vismodegib (GB29764 study), pirfenidone±sildenafil, nintedanib+/-sildenafil (INSTAGE study) and other clinical trials in progress such as NCT02606877 (nintedanib+pirfenidone and the INMARK study.”

- Page 5, the section title “Pulmonary Emphysema” should be replaced by: “Combined pulmonary fibrosis and emphysema (CPFE)”.

- Page 5, section “Pulmonary Emphysema”, line 1. Where it says: “No effective treatment is currently available for combined pulmonary fibrosis and emphysema (CPFE) syndrome,<sup>35,36</sup> so it seems logical to base therapeutic decisions on the separate recommendations for emphysema and IPF.”, it should say: “No effective treatment is currently available for pulmonary syndrome,<sup>35,36</sup> so it seems logical to base therapeutic decisions on the separate recommendations for emphysema and IPF.”